UroGen Pharma Ltd. reported third quarter 2025 financial results with total revenue of $27.5 million, up from $25.2 million in the same period last year. For the nine months ended September 30, 2025, revenue reached $72.0 million, compared to $65.8 million for the same period in 2024. As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $127.4 million, down from $241.7 million at December 31, 2024. Total assets stood at $185.0 million, with total liabilities at $300.5 million and a total shareholders' deficit of $115.4 million. ZUSDURI achieved net product revenue of $1.8 million in the third quarter, with preliminary October demand revenue estimated at $4.5 million. JELMYTO recorded net product revenue of $25.7 million in the third quarter, reflecting a 13% year-over-year growth in underlying demand revenue. UroGen expects full-year 2025 operating expenses to range from $215 to $225 million, including $11 to $14 million in non-cash share-based compensation expense. The company also noted the FDA agreement to submit a New Drug Application for UGN-103, following results from the Phase 3 UTOPIA trial.